You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 12,201,604

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,201,604

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US18/416,748
Patent Claims:	1. A method of treating a patient suffering from a circadian rhythm disorder, the method comprising internally administering to the patient tasimelteon once daily in an amount effective to shift a free running cortisol circadian rhythm in the patient toward a 24-hour circadian rhythm. 2. The method of claim 1, wherein the patient is light perception impaired (LPI). 3. The method of claim 1, wherein the patient is totally blind. 4. The method of claim 1, wherein the patient suffers from Non-24-Hour Sleep-Wake Disorder. 5. The method according to claim 1, wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours. 6. The method of claim 1, wherein the tasimelteon is effective to entrain the patient's melatonin circadian rhythm to a 24-hour circadian rhythm. 7. The method of claim 1, wherein the effective amount is between about 10 mg and about 100 mg per day. 8. The method of claim 7, wherein the effective amount is between about 20 mg and about 50 mg per day. 9. The method of claim 8, wherein the effective amount is about 20 mg per day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.